WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

WilmerHale Advises Argos Therapeutics in Pricing of $50M Public Offering

Firm News

Related Solutions

Leveraging our sophisticated technical, market and legal experience to help clients effectively and efficiently manage complex transactions and get the deal done.
Advising life sciences innovators, investors and industry leaders on complex transactions, legal issues and business challenges.

Argos Therapeutics, Inc., an immuno-oncology company focused on the development and commercialization of individualized immunotherapies for the treatment of cancer based on the Arcelis® technology platform, announced the pricing of its public offering of $50 million. 

The WilmerHale team was led by Partner Stuart Falber and included Associate Leora Rodenstein, Senior Associate Ryan Mitteness, Associate Andrea Sorrentino, Attorney Heidi Treiber and Senior Associate Mia Kelley. Partner Julie Hogan Rodgers and Associate Leah Segal (Tax) were also involved.

Read Argos Therapeutics' press release for more information.

Notice

We appreciate your interest in WilmerHale. While we are pleased to have you contact us, please keep in mind that merely contacting WilmerHale does not create an attorney-client relationship. Such a relationship will not arise until the Firm agrees in writing to represent you in connection with a particular matter. Importantly, unless and until this has occurred, you should not provide us with any confidential information, and we have no duty to keep confidential any information that we may receive from you. Thank you for your understanding.

I Accept Cancel